Publications by authors named "Jing Lue"
While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival. Enzastaurin as a potent inhibitor of PKC-β and PI3K/AKT pathway suppressor has been tested in many clinical trials including two key studies in DLBCL: Phase III maintenance study (Preventing Relapse in Lymphoma Using Daily Enzastaurin [PRELUDE]) and a first-line Phase II study (S028). DNA extracted from PRELUDE patients' blood samples was retrospectively genotyped identifying a novel genetic biomarker, DGM1 that showed high correlation with response to enzastaurin.
View Article and Find Full Text PDFPlasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.
Front Aging Neurosci
July 2017
Article Synopsis
- The study compares plasma amyloid beta (Aβ42) and tau levels in Alzheimer's disease (AD) patients from two different hospitals in the U.S. and Taiwan using ultra-sensitive IMR assays.
- Significant increases in tau levels were found in AD patients from both cohorts, while Aβ42 levels only increased in the Taiwan group.
- The research determined that tau levels could identify probable AD with high accuracy, and combining Aβ42 and tau data further improved diagnostic accuracy, suggesting these measures can help in diagnosing AD clinically.